MedPath

UNIVERSITY OF SOUTH FLORIDA

UNIVERSITY OF SOUTH FLORIDA logo
🇺🇸United States
Ownership
Private
Established
1956-01-01
Employees
10K
Market Cap
-
Website
http://www.usf.edu

An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

Phase 4
Completed
Conditions
Gout
Interventions
Other: Magnetic Resonance Imaging
First Posted Date
2010-04-29
Last Posted Date
2019-08-07
Lead Sponsor
University of South Florida
Target Recruit Count
74
Registration Number
NCT01112982
Locations
🇺🇸

University of South Florida Medical Clinics, Tampa, Florida, United States

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

Completed
Conditions
Multiple Sclerosis
First Posted Date
2010-02-11
Last Posted Date
2012-06-18
Lead Sponsor
University of South Florida
Target Recruit Count
20
Registration Number
NCT01067573
Locations
🇺🇸

USF Health, Tampa, Florida, United States

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Phase 4
Completed
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
First Posted Date
2009-11-23
Last Posted Date
2021-11-09
Lead Sponsor
University of South Florida
Target Recruit Count
23
Registration Number
NCT01018264
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

University of Miami, Miami, Florida, United States

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Phase 2
Completed
Conditions
Breast Cancer
Cardiac Toxicity
Interventions
First Posted Date
2009-11-09
Last Posted Date
2021-03-30
Lead Sponsor
University of South Florida
Target Recruit Count
468
Registration Number
NCT01009918
Locations
🇺🇸

Illinois CancerCare - Havana, Havana, Illinois, United States

🇺🇸

Saint Luke's Hospital, Chesterfield, Missouri, United States

🇺🇸

Illinois CancerCare - Canton, Canton, Illinois, United States

and more 171 locations

Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

Phase 2
Completed
Conditions
Spinocerebellar Ataxia Type 3
Interventions
Drug: placebo
First Posted Date
2009-10-09
Last Posted Date
2012-06-18
Lead Sponsor
University of South Florida
Target Recruit Count
20
Registration Number
NCT00992771
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

University of California - Los Angeles, Los Angeles, California, United States

Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer

Phase 2
Terminated
Conditions
Leukemia
Lymphoma
Malnutrition
Myelodysplastic Syndromes
Unspecified Childhood Solid Tumor, Protocol Specific
Weight Changes
Interventions
Dietary Supplement: Ensure
Dietary Supplement: PediaSure
First Posted Date
2009-07-30
Last Posted Date
2014-04-02
Lead Sponsor
University of South Florida
Target Recruit Count
9
Registration Number
NCT00949117

Strategies To Prevent Pneumonia 2 (SToPP2)

Phase 2
Completed
Conditions
Ventilator-Associated Pneumonia
Mechanical Ventilation Complication
Infections, Hospital
Interventions
Procedure: Pre-intubation CHX
Procedure: Control
First Posted Date
2009-05-06
Last Posted Date
2016-01-11
Lead Sponsor
University of South Florida
Target Recruit Count
314
Registration Number
NCT00893763
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder

Phase 2
Completed
Conditions
Obsessive Compulsive Disorder
Interventions
Behavioral: Wait-list control
Behavioral: Cognitive-behavioral therapy
First Posted Date
2009-04-15
Last Posted Date
2015-06-11
Lead Sponsor
University of South Florida
Target Recruit Count
31
Registration Number
NCT00881465
Locations
🇺🇸

University of South Florida, St. Petersburg, Florida, United States

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Not Applicable
Completed
Conditions
Precancerous Condition
Interventions
First Posted Date
2009-04-13
Last Posted Date
2021-02-21
Lead Sponsor
University of South Florida
Target Recruit Count
20
Registration Number
NCT00879879
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer

Not Applicable
Withdrawn
Conditions
Pulmonary Complications
Radiation Fibrosis
Dyspnea
Lung Cancer
Interventions
First Posted Date
2009-04-13
Last Posted Date
2017-05-02
Lead Sponsor
University of South Florida
Registration Number
NCT00880386
© Copyright 2025. All Rights Reserved by MedPath